Hence, the advantage of our novel mRNA-76-cLNP compound as described above in the context of ARDS is its ability to be delivered and to act in a highly spatially restricted manner, enabling the Tie2 agonist to rapidly and almost exclusively target the specific site of the endothelial capillary bed where the pathophysiological lung edema occurs. The gene discussed is TEK; the disease is acute respiratory distress syndrome.